Fertility considerations in nerve-sparing retroperitoneal lymph-node dissection
- 1 June 1994
- journal article
- clinical trial
- Published by Springer Nature in World Journal of Urology
- Vol. 12 (3) , 136-138
- https://doi.org/10.1007/bf00192270
Abstract
Nerve-sparing retroperitoneal lymph-node dissection (RPLND) maintains the patient's ability to ejaculate postoperatively. However, since testicular cancer patients sometimes have diminished spermatogenesis, questions have been raised as to the advisability of nerve preservation relative to ultimate fertility. Fertility status was assessed in clinical stage A patients by two methods. These included standard semen analysis and a post-RPLND survey. The results show that approximately 75% of non-seminomatous testicular cancer patients who present in clinical stage A have fertility potential as based on semen analysis. Additionally, of those patients responding to the post-RPLND survey who had attempted pregnancy following RPLND, 76% reported attainment of pregnancy. Nerve-sparing RPLND maintains fertility potential in clinical stage I patients; furthermore, this fertility potential appears to be worth preserving as many patients will be capable of impregnating their partners.Keywords
This publication has 4 references indexed in Scilit:
- Primary Chemotherapy for Stage II Nonseminomatous Germ Cell Tumors of the TestisJournal of Urology, 1994
- Retroperitoneal Lymphadenectomy for Clinical Stage a Testis Cancer (1965 to 1989): Modifications of Technique and Impact on EjaculationJournal of Urology, 1993
- Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.Journal of Clinical Oncology, 1992
- Fertility Issues in the Therapy of Nonseminomatous Testicular TumorsUrologic Clinics of North America, 1987